A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-12

Study Completion Date

2014-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and tolerability of the study drug (DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to receive DX-2930 or placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

NCT02586805

Hereditary Angioedema (HAE)

COMPLETED PHASE3

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

NCT02741596

Hereditary Angioedema (HAE)

COMPLETED PHASE3

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00262080

Hereditary Angioedema (HAE)

COMPLETED PHASE3

EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema

NCT01826916

Hereditary Angioedema (HAE)

COMPLETED PHASE2

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema

NCT02870972

Hereditary Angioedema (HAE)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 32 healthy subjects will be randomized to receive DX-2930 or placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Angioedema (HAE)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DX-2930

DX-2930 administered by subcutaneous route

Group Type EXPERIMENTAL

DX-2930

Intervention Type DRUG

placebo

inactive formulation of DX-2930

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo, subcutaneous administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DX-2930

Intervention Type DRUG

Placebo

placebo, subcutaneous administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects who are 18 to 55 years of age, inclusive.
2. Willing and able to read, understand, and sign an informed consent form.
3. Willing and able to receive subcutaneous injections.
4. Body mass index (BMI) of 18 to 33 kg/m2 with a weight of at least 60 kg for males and at least 50 kg for females, with a maximum weight of 130 kg for any subject.
5. Medically healthy as determined by the investigator via assessment of physical examination, medical history, clinical laboratory tests, vital signs, and electrocardiogram (ECG).
6. Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through 30 days after the final study visit: condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or intra-uterine device (IUD). A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception. Female subjects must agree to practice the above birth control methods for 30 days after the final study visit as a safety precaution.
7. Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening follicle-stimulating hormone (FSH) level in the post-menopausal range), do not require contraception during the study.
8. Males with female partners of childbearing potential must agree to use a highly effective, medically acceptable form of contraception from the screening period through 60 days after the final study visit. All male subjects, including males who are surgically sterile (post vasectomy), must agree to practice the above birth control methods for 60 days from the final study visit as a safety precaution.

Exclusion Criteria

1. Any active acute or chronic illness at screening.
2. Any history of exposure to a biologic within 90 days prior to dosing.
3. Receipt of any investigational (a non-licensed, non-approved) drug or device within 60 days prior to dosing.
4. Any prior history of exposure to a monoclonal antibody.
5. Pregnant or actively breastfeeding.
6. Any history of substance abuse or dependence.
7. Positive urine drug or alcohol test at screening or Day -1 for amphetamines, benzodiazepines, barbiturates, cocaine, cotinine (detection mechanism for nicotine), marijuana, opiates, phencyclidine or ethanol.
8. Regular use of alcohol within six months prior to the screening visit \[more than fourteen units of alcohol per week (1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol)\].
9. Use of prescription or over-the-counter medication within 14 days prior to administration of study medication, or use of over-the-counter products (dietary or herbal supplements and vitamins) within 14 days prior to administration of study medication.
10. Use of nicotine or nicotine-containing products within the previous three months prior to screening.
11. Subject has any other condition, which in the opinion of the investigator may compromise the safety or compliance or would preclude the subject from successful completion of the study or interfere with the interpretation of the results.
12. Abnormal clinical laboratory values and/or other study assessments such as ECG results deemed to be clinically significant by the investigator.
13. Donation of blood within 60 days preceding Study Day -1.
14. Serology testing positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes